Photo credit: www.sciencedaily.com
Microglia, the brain’s specialized immune cells, play a crucial role in maintaining cerebral health. They are responsible for eliminating pathogens and clearing away cellular waste, including the plaques associated with Alzheimer’s disease. However, as the brain ages, the behavior of microglia shifts. While some retain their protective functions, others begin to falter and can produce small quantities of inflammatory signals.
One noteworthy inflammatory signal is interleukin-12 (IL-12). Through in-depth analyses, research teams led by Professor Frank Heppner from Charité — Universitätsmedizin Berlin and Professor Nikolaus Rajewsky from the Max Delbrück Center for Molecular Medicine have uncovered how IL-12 may initiate and hasten the progression of Alzheimer’s dementia. Their findings, published in the journal “Nature Aging,” have the potential to inform the development of novel combination therapies.
For many years, research on Alzheimer’s disease primarily centered on the roles of amyloid-beta and tau proteins, with inflammation relegated to a secondary status. According to Heppner, the perspective is shifting. “We are beginning to acknowledge that inflammatory processes may actually be central to disease advancement,” he asserts. In a pivotal study in 2012, Heppner’s research group discovered that inhibiting IL-12 and IL-23 led to a marked reduction in Alzheimer’s-related changes in murine models. Nonetheless, Heppner indicates that traditional methods were insufficient for uncovering the underlying mechanisms, leading him to seek out Rajewsky’s expertise in single-cell analysis.
Complexities of Brain Cell Interactions
Cells adapt to external influences throughout their lifespan by using their genetic blueprint. Single-cell analysis allows researchers to observe these adaptive processes, mapping gene expression and protein production across thousands of individual cells at once. This method generates extensive datasets that can be examined using artificial intelligence and machine learning. However, one significant challenge in single-cell sequencing is the effective isolation of individual cells from their tissue environment without causing damage or changes. As Rajewsky describes, “In aging mouse brains, particularly those affected by Alzheimer’s plaques, separating cells cleanly is exceptionally challenging due to their entanglement.”
Over several years, Rajewsky’s team developed a workaround that does not rely on isolating whole cells. They extracted cell nuclei from brain tissue and analyzed the RNA content. By correlating their findings with existing databases like the Allen Brain Atlas, they ensured their methodology captured a diverse representation of cell types. In their study, they sequenced RNA from over 80,000 cell nuclei, creating tailored workflows for data processing and cell interaction modeling. Rajewsky emphasizes the importance of this collaborative effort: “This meticulous early optimization was crucial—without it, we would not have identified these connections.”
Understanding IL-12’s Role in Alzheimer’s Pathology
Historically linked to autoimmune disorders, IL-12 has emerged as a critical factor in the development of Alzheimer’s disease. It inflicts damage on two vital types of brain cells: mature oligodendrocytes, responsible for myelin production—a protective sheath around nerve fibers—and interneurons, which are crucial for cognitive functions and memory. The interaction between IL-12 and interneurons leads to their degeneration, initiating a detrimental cycle: increased IL-12 production results in further neuronal damage, which, in turn, overwhelms the remaining functional microglia in their role of clearing away cellular debris, including amyloid plaques.
To validate this mechanism, the researchers conducted experiments using both murine models and human tissue samples. When IL-12 was inhibited in cell cultures and mouse models, disease-related alterations were significantly mitigated. High-resolution electron microscopy images from the Max Planck Institute illustrated variations in myelin structure and nerve fiber density dependent on the presence or absence of IL-12 signaling. Additionally, lipidomic analyses at the University of Zurich highlighted changes in the composition of the myelin sheath. Investigations of post-mortem brain tissue from Alzheimer’s patients further confirmed a direct correlation between disease progression and IL-12 levels.
Implications for Combination Therapy
“We now possess a comprehensive understanding of this mechanism, with single-cell technologies being instrumental,” says Heppner, who also leads a neuroimmunology group at the Deutsche Zentrum für Neurodegenerative Erkrankungen (DZNE). He raises an important question regarding whether IL-12 primarily affects oligodendrocytes, interneurons, or both concurrently.
This study holds immediate value, as several existing medications are designed to inhibit IL-12. The research team hopes to encourage clinicians to initiate clinical trials based on their discoveries. Heppner suggests that if these medications prove successful, they could represent a significant addition to therapeutic strategies. “Alzheimer’s isn’t driven by a single factor. One dimension of the disease is influenced by the immune system, at least in certain individuals. Slowing neurodegeneration may necessitate a combination of therapies,” he explains. Such therapeutic interventions could potentially occur early in the disease trajectory, given that IL-12 levels can be quantified in blood or cerebrospinal fluid.
Furthermore, the teams at Charité and the Max Delbrück Center are investigating a new avenue: whether microplastics in the brain could stimulate microglia to produce IL-12. Rajewsky proposes, “Microglia may struggle to handle microplastics, triggering inflammatory responses.” This theory posits a possible connection between environmental exposure and the proliferation of neurodegenerative diseases, although it remains to be substantiated. Both research groups consider this hypothesis a promising and essential direction for future exploration.
Source
www.sciencedaily.com